COMPANY
Vaxxinity
Timeline
- Trial start Phase 1: A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants source ↗
- Trial start 1: A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants source ↗
- Trial start Phase 3: Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine source ↗
- Trial start Phase 2/Phase 3: A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05477095 | A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants | 1 | Completed | Jul 6, 2022 | Oct 6, 2023 (actual) |
| NCT05762276 | A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants | Phase 1 | Unknown status (ClinicalTrials.gov) | Mar 7, 2023 | Jun 27, 2024 (estimated) |
| NCT05293665 | Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine | Phase 3 | Unknown status (ClinicalTrials.gov) | Mar 16, 2022 | 2022-11 (estimated) |
| NCT04683224 | A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine | Phase 2/Phase 3 | Withdrawn | Feb 1, 2021 | Mar 22, 2023 (estimated) |